Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

2.

Alterations of ER, PR, HER-2/neu, and P53 protein expression in ductal breast carcinomas and clinical implications.

Liu C, Zhang H, Shuang C, Lu Y, Jin F, Xu H, Lu P.

Med Oncol. 2010 Sep;27(3):747-52. doi: 10.1007/s12032-009-9279-8.

PMID:
19657752
4.

Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma.

Ariga R, Zarif A, Korasick J, Reddy V, Siziopikou K, Gattuso P.

Breast J. 2005 Jul-Aug;11(4):278-80.

PMID:
15982396
5.

Schirrous invasive ductal carcinoma of the breast overexpress p53 oncoprotein.

Ferrini FS, Rossi MA, Neto MM, Soares FA.

Sao Paulo Med J. 2001 Jan 4;119(1):4-6.

6.

Correlations among p53, Her-2/neu, and ras overexpression and aneuploidy by multiparameter flow cytometry in human breast cancer: evidence for a common phenotypic evolutionary pattern in infiltrating ductal carcinomas.

Smith CA, Pollice AA, Gu LP, Brown KA, Singh SG, Janocko LE, Johnson R, Julian T, Hyams D, Wolmark N, Sweeney L, Silverman JF, Shackney SE.

Clin Cancer Res. 2000 Jan;6(1):112-26.

7.
8.

Mitochondrial DNA alterations correlate with the pathological status and the immunological ER, PR, HER-2/neu, p53 and Ki-67 expression in breast invasive ductal carcinoma.

Lin CS, Chang SC, Ou LH, Chen CM, Hsieh SS, Chung YP, King KL, Lin SL, Wei YH.

Oncol Rep. 2015 Jun;33(6):2924-34. doi: 10.3892/or.2015.3887.

PMID:
25845386
9.

Differences in the pathologic and molecular features of intraductal breast carcinoma between younger and older women.

Rodrigues NA, Dillon D, Carter D, Parisot N, Haffty BG.

Cancer. 2003 Mar 15;97(6):1393-403.

10.
11.
13.

Histological grade, p53, HER2 and hormone receptor status of synchronous bilateral breast carcinoma.

Matsuo K, Fukutomi T, Akashi-Tanaka S, Hasegawa T, Tsuda H.

Breast Cancer. 2002;9(2):127-33.

PMID:
12016392
14.

Expression and mutational analysis of GATA3 in Malaysian breast carcinomas.

Bong PN, Zakaria Z, Muhammad R, Abdullah N, Ibrahim N, Emran NA, Syed Hussain SN.

Malays J Pathol. 2010 Dec;32(2):117-22.

15.

Molecular subtyping of breast cancer from traditional tumor marker profiles using parallel clustering methods.

Ambrogi F, Biganzoli E, Querzoli P, Ferretti S, Boracchi P, Alberti S, Marubini E, Nenci I.

Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):781-90.

16.

Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ.

Bijker N, Peterse JL, Duchateau L, Robanus-Maandag EC, Bosch CA, Duval C, Pilotti S, van de Vijver MJ.

Br J Cancer. 2001 Feb;84(4):539-44.

17.

Simultaneous bilateral breast carcinomas: a category with frequent coexpression of HER-2 and ER-alpha, high Ki-67 and bcl-2, and low p53.

Bassarova AV, Nesland JM, Sedloev T, Lilleby W, Hristova SL, Trifonov DY, Torlakovic E.

Int J Surg Pathol. 2005 Jul;13(3):239-46.

PMID:
16086078
19.

Prognostic variables in invasive breast cancer: contribution of comedo versus noncomedo in situ component.

Brower ST, Ahmed S, Tartter PI, Bleiweiss I, Amberson JB.

Ann Surg Oncol. 1995 Sep;2(5):440-4.

PMID:
7496840
20.

Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study.

Joensuu H, Isola J, Lundin M, Salminen T, Holli K, Kataja V, Pylkkänen L, Turpeenniemi-Hujanen T, von Smitten K, Lundin J.

Clin Cancer Res. 2003 Mar;9(3):923-30.

Items per page

Supplemental Content

Support Center